Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 9.18% Barclays $913 → $1025 Maintains Overweight 07/05/2024 8.97% Morgan Stanley $1023 → $1023
Eli Lilly Announces CFO Change
Shares of Eli Lilly And Company (NYSE:LLY) announced that its Chief Financial Officer, Anat Ashkenazi, has resigned to pursue a new career. Gordon Brooks has been appointed as the interim CFO,
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity
Competitor Analysis: Evaluating UnitedHealth Group And Competitors In Health Care Providers & Services Industry
In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an
AbbVie Names New R&D Head
Eli Lilly Announces CFO Anat Ashkenazi Resigns To Pursue New Career; Gordon Brooks Appointed Interim CFO Effective July 15, 2024
Eli Lilly Announces CFO Anat Ashkenazi Resigns To Pursue New Career; Gordon Brooks Appointed Interim CFO Effective July 15, 2024
Most Patients Discontinue Novo's Wegovy, Ozempic Within Two Years: Report
Leading PBMs to Face Congressional Hearing on July 23: Axios
BMO Sees BMRN, LEGN, SLN as Attractive M&A Targets
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.Lead asset MORF-057 is a small-molecule
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' to Meet 2024 Guidance, Goldman Says
U.S. pharma giant Johnson & Johnson (NYSE:JNJ) will report its second-quarter 2024 earnings on Wednesday, July 17.As per data from Benzinga Pro, analysts estimate sales of $22.29 billion and
FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth
The U.S. Federal Trade Commission (FTC) has highlighted significant concerns regarding consolidating pharmacies and health insurance companies, focusing on the influence of a few dominant pharmacy
Citi Research's AI Hedge Stocks - Part II
Cantor Fitzgerald Reiterates Overweight on UnitedHealth Group, Maintains $591 Price Target
Cantor Fitzgerald analyst Sarah James reiterates UnitedHealth Group (NYSE:UNH) with a Overweight and maintains $591 price target.
UnitedHealth Group Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 19.79% Cantor Fitzgerald $591 → $591 Reiterates Overweight → Overweight 06/12/2024 19.79%
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Financial giants have made a conspicuous bullish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co (NYSE:LLY) revealed 56 unusual trades.Delving into the details, we
UnitedHealth Group Unusual Options Activity For July 09
Financial giants have made a conspicuous bullish move on UnitedHealth Group. Our analysis of options history for UnitedHealth Group (NYSE:UNH) revealed 15 unusual trades.Delving into the details, we
Pharma Middlemen Benefit at the Expense of Patients: FTC
Shares of Novo Nordisk fell, and research shows that the weight-loss drug of Eli Lilly and Co has a faster and more significant effect.
According to research analysis, the weight-loss effect of Eli Lilly's drug is better than that of Novo-Nordisk. Novo-Nordisk's stock price fell in pre-market trading on Tuesday. A study published on Monday in JAMA Internal Medicine showed that Mounjaro, Eli Lilly's treatment drug, had a more significant effect on weight loss than Novo-Nordisk's competitor. The study reviewed health records and other data to evaluate the active ingredients tirzepatide (the active ingredient in Eli Lilly's Mounjaro and Zepbound) and semaglutide (
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 20.11% Cantor Fitzgerald $200 → $200 Reiterates Overweight → Overweight 07/02/2024 14.11%